NASDAQ: BTTX - Better Therapeutics, Inc.

Yield per half year: -99.12%
Sector: Healthcare

Share chart Better Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions.

more details
In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

EBITDA -0.0057
EV/EBITDA -0.7443
IPO date 2021-10-28
ISIN US08773T1043
Industry Biotechnology
P/BV 3.35
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 1.8E-5
Сайт https://www.bettertx.com
Цена ао 0.0137
Число акций ао 0.02356 млрд
Change price per day: 0% (0.0001)
Change price per week: 0% (0.0001)
Change price per month: 0% (0.0001)
Change price per 3 month: 0% (0.0001)
Change price per half year: -99.12% (0.0113)
Change price per year: -99.95% (0.195)
Change price per 3 year: -100% (4.65)
Change price per 5 year: 0% (0.0001)
Change price per 10 year: 0% (0.0001)
Change price per year to date: 0% (0.0001)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV -35.64 0
P/E 0 0
EV/EBITDA -0.8149 0
Total: 2.5

Efficiency

Title Value Grade
ROA, % -107.6 0
ROE, % -221.99 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.389 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 523.39 10
Yield EPS, % 217.59 10
Total: 8
More

Institutions Volume Share, %
MMCAP International, Inc. SPC 356270 0.71
Citadel Advisors Llc 216165 0.43
Vanguard Group Inc 198154 0.4
Geode Capital Management, LLC 168821 0.34
Millennium Management LLC 128749 0.26
Blackrock Inc. 88635 0.18
Capital Investment Advisory Services, LLC 71000 0.14
State Street Corporation 58600 0.12
Susquehanna International Group, LLP 38057 0.08
Corient Private Wealth LLC 29180 0.06



Head Job title Payment Year of birth
Mr. David P. Perry M.B.A. Co-Founder & Executive Chairman 260k 1968 (57 years)
Mr. Frank L. Karbe CEO, Interim CFO, President & Director 533.37k 1968 (57 years)
Dr. Mark A. Berman M.D. Chief Medical Officer 573.75k 1976 (49 years)
Ms. Kristin Wynholds Chief Product Officer 519.07k 1973 (52 years)
Mr. Andres Camacho Senior VP of Technology & Head of Engineering N/A
Ms. Angela Willis Senior Vice President of Market Access N/A
Leslie Miller Controller N/A
Ms. Jessica Meng Chief Commercial Officer N/A

Address: United States, San Francisco. CA, 548 Market Street - open in Google maps, open in Yandex maps
Website: https://www.bettertx.com